期刊文献+

冠状动脉无复流患者内皮微粒变化的临床意义 被引量:4

Changes of endothelial microparticles and slCAM - 1 in AMI patients with no - reflow after per- cutaneous coronary intervention
下载PDF
导出
摘要 目的评价急性心肌梗死(AMI)行急诊冠脉介入治疗(PcI)后发生无复流患者循环血中内皮微粒(EMP)和可溶性细胞间黏附分子-1(sICAM-1)变化的临床意义。方法将行急诊PCI治疗的AMI患者64例根据术后TIMI血流分级随机分为两组,冠状动脉前向血流≤TMI2级23例为无复流组,TIMI3级41例为再灌注组,另以20例健康人为对照组。分别于急诊入院时、再灌注后即刻和再灌注后24h采集静脉血,采用流式细胞术(FCM)测定患者血浆EMP水平,采用酶联免疫吸附法(ELISA)测定血清sICAM—1水平。结果再灌注组和无复流组各时点EMP和sICAM-1水平明显高于对照组(P均〈0.05);无复流组各时点EMP和sICAM—1水平明显高于再灌注组(P均〈0.05);再灌注组和无复流组再灌注后即刻和再灌注后24hEMP和slCAM—l水平仍高于入院时(P均〈0.05)。EMP与sICAM—1水平呈正相关(r=0.35,P:0.003)。结论EMP在评价PCI术后无复流患者冠脉内皮炎症反应和损伤程度方面具有一定的临床意义。 Objective To evaluate the clinical value of endothelial microparticles (EMP) and soluble intercellular adhesion molecule - 1 ( sICAM - 1 ) as specific markers of endothelial dysfunction in acute myocardial infarction ( AMI ) patients with no - reflow after primary percutaneous coronary intervention ( PCI ). Methods 64 patients of AMI with PCI were randomly divided into no - reflow group (n = 23) and the reperfusion group (n = 41 ), and 20 healthy subjects (control group) were enrolled in the study. TIMI flow was examined angiographically after PCI. EMP was measured by flow cytometry ( FCM ) and level of sICAM - 1 was tested by enzyme linked immunosorbent assay ( ELISA ). Resulfs Compared with the control group, no - reflow group and reperfusion group had higher level of EMP and sICAM - 1 at all time points ( P 〈 0.05 ). The levels of EMP and sICAM - 1 in no - reflow group were markedly increased, compared with the reperfusion group at all time points (P 〈 0.05 ). The levels of EMP and sICAM - 1 in no - reflow group and the reperfusion group were significantly higher at immediate time point and 24 h time point than at admission to hospital ( P 〈 0.05 ). There were positive correlation between EMP and sICAM - 1 ( r = 0.35, P = 0. 003 ). Conclusion The EMP and sICAM may be of clinical significance in evaluating the endothelial inflammation and dysfunction of AMI patients with no - reflow after PCI.
出处 《中国急救医学》 CAS CSCD 北大核心 2009年第12期1070-1073,共4页 Chinese Journal of Critical Care Medicine
关键词 经皮冠脉介入治疗 无复流 内皮微粒 细胞间黏附分子-1 Percutaneous coronary intervention No - reflow Endothelial microparticles Intercellular adhesion molecule - 1
  • 相关文献

参考文献2

二级参考文献26

  • 1杨跃进,赵京林,荆志成,吴永健,尤士杰,杨伟宪,孟亮,田毅,陈纪林,高润霖,陈在嘉.中药通心络对猪急性心肌梗死再灌注后无再流的影响[J].中华医学杂志,2005,85(13):883-888. 被引量:34
  • 2杨跃进,赵京林.应重视急性心肌梗死再灌注后无再流的防治[J].中华医学杂志,2005,85(31):2169-2170. 被引量:5
  • 3赵京林,杨跃进,尤士杰,荆志成,吴永建,杨伟宪,陈纪林,高润霖,陈在嘉.通心络对猪急性心肌梗死再灌注后内皮素-1的影响[J].中国中西医结合杂志,2005,25(10):902-906. 被引量:11
  • 4杨跃进,赵京林,孟亮,田毅,荆志成,吴永建,尤士杰,杨伟宪,陈纪林,高润林,陈在嘉.中药通心络(超微粉碎)对猪急性心肌梗死再灌注后无再流的影响[J].中国中西医结合杂志,2006,26(1):49-53. 被引量:34
  • 5Kelly RV, Cohen MG, Runge MS, et al. The no-reflow phenomenon in coronary arteries. J Thromb Haemost, 2004, 2: 1903 -1907.
  • 6Lindsey M, Wedin K, Michael D, et al. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation, 2001, 103 : 2181-2187.
  • 7Peter AV, Kanyan X, Kathleen M, et al. VE-cadherin: adhesion at arm's length. Am J Physiol Cell Physiol, 2004, 286:987-997.
  • 8Dejana E, Spagnuolo R, Bazzoni G. Interendothelial junctions and their role in the control of angiogenesis, vascular permeability and leukocyte transmigration. Thmmb Haemost, 2001, 86 : 308-315.
  • 9Zhao X, Alexander JS, Zhang S, et al. Redox regulation of endothelial barrier integrity. Am J Physiol Lung Cell Mol Physiol, 2001, 281 : L879-L886.
  • 10Barandon L, Couffinhal T, Ezam J, et al. Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation, 2003, 108 : 2282-2289.

共引文献29

同被引文献30

  • 1沙建平,薛耀明,陈炫,祝彼得,张新胜,陈卫银,冯本华,赵艳.重组葡激酶对重症急性胰腺炎大鼠胰腺组织缺血的影响[J].中国危重病急救医学,2007,19(8):467-470. 被引量:3
  • 2Shereif,Rezkalla,Robert A.No-reflow phenomenon Circulation[J].2002,105(5):656-662.
  • 3Alexander O.Spiel,James C.Gilbert,Bernd Jilma.Von Willebrand Factor in Cardiovascular Disease:Focus on Acute Coronary Syndromes[J].Circulation,2008,117(11):1449-1459.
  • 4Niccoli C,Giubilatos,Russo E,et al.Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention[J].Eur Heart J,2008,29(15):1843-1850.
  • 5Giampaolo Niccoli,Francesco Burzotta,Leonarda Galiuto,et al.Myocardial No-Reflow in Humans[J].Journal of the American College of Cardiology,2009,54(4):282-292.
  • 6J Evan Sadler.Von willebrand factor,ADAMTS13,and thrombotic thrombocytopenic purpura[J].Blood,2008,112(1):11-18.
  • 7Sgueglia GA,Niccoli G,Spaziani C,et al,Baseline von Willebrand factor plasma levels and no-reflow phenomenon after primary percutaneous coronary intervention for ST segment elevation myocardial infarction[J].Int J Cardiol,2010,145(2):230-232.
  • 8Murat Sezer,Irem Okcular,Taner Goren,et al.Association of haematological indices with the degree of microvascular injury in patients with acute anterior wall myocardial infarction treated with primary percutaneous coronary intervention[J].Heart,2007,93(3):313-318.
  • 9Huczek Z,Kochman J,Filipiak KJ,et al.Mean platelet volume on admission predicts impaired reperfusion and long-term mortality in acute myocardial infarction treated with primary percutaneous coronary intervention[J].J Am Coll Cardiol,2005,46(2):284-290.
  • 10Crawley JTB,Lane DA,Woodward M,et al.Evidence that high von Willebrand factor and low ADAMTS-13levels independently increase the risk of a non-fatal heart attack[J].J Thromb Haemost,2008,6(4):583-588.

引证文献4

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部